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Background aims: Mesenchymal stromal cells (MSCs) isolated from various tissues are under investigation as
cellular therapeutics in a wide range of diseases. It is appreciated that the basic biological functions of MSCs
vary depending on tissue source. However, in-depth comparative analyses between MSCs isolated from dif-
ferent tissue sources under Good Manufacturing Practice (GMP) conditions are lacking. Human clinical-grade
low-purity islet (LPI) fractions are generated as a byproduct of islet isolation for transplantation. MSC isolates
were derived from LPI fractions with the aim of performing a systematic, standardized comparative analysis
of these cells with clinically relevant bone marrow-derived MSCs (BMMSCs).
Methods: MSC isolates were derived from LPI fractions and expanded in platelet lysate-supplemented medium or
in commercially available xenogeneic-free medium. Doubling rate, phenotype, differentiation potential, gene
expression, protein production and immunomodulatory capacity of LPIs were comparedwith those of BMMSCs.
Results:MSCs can be readily derived in vitro from non-transplanted fractions resulting from islet cell process-
ing (i.e., LPI MSCs). LPI MSCs grow stably in serum-free or platelet lysate-supplemented media and demon-
strate in vitro self-renewal, as measured by colony-forming unit assay. LPI MSCs express patterns of
chemokines and pro-regenerative factors similar to those of BM MSCs and, importantly, are equally able to
attract immune cells in vitro and in vivo and suppress T-cell proliferation in vitro. Additionally, LPI MSCs can
be expanded to therapeutically relevant doses at low passage under GMP conditions.
Conclusions: LPI MSCs represent an alternative source of GMP MSCs with functions comparable to BMMSCs.
© 2020 International Society for Cell & Gene Therapy.
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Mesenchymal stromal cells (MSCs) are multipotent cells found in
variable numbers in the majority of tissues. Their immunoregulatory,
pro-regenerative and differentiation potential, coupled with their rel-
ative ease of procurement, has made them attractive as cellular ther-
apeutics [1]. Currently, there are over 1300 registered clinical trials
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ease and transplant settings [2]. Historically, the majority of the clini-
cal data has been generated using bone marrow-derived MSCs (BM
MSCs); therefore, much of the understanding of MSC function relates
to BM cells. Although living donor bone marrow donation is well
established, bone marrow aspirates contain relatively low numbers
of MSCs that require extensive expansion to reach therapeutic doses
[3], and the ease of generating therapeutically relevant doses of func-
tional MSCs reduces with increasing donor age [4,5]. BM MSCs
expanded at a large scale show a degree of phenotypic and functional
variation over time [6]. These passage-dependent functional and phe-
notypical changes may underlie an observed decline in in vivo func-
tion; for example, BM MSCs are more efficacious when used at lower
passage in patients with graft-versus-host disease (GVHD) [7]. As a
result, BM MSCs may not be ideal for every therapeutic situation;
therefore, there has been a concerted effort to look for alternative tis-
sue sources, including adipose tissue and umbilical cord [810].
MSCs isolated from different sources are not identical in their biologi-
cal function, with differences including immunosuppressive ability
and angiogenic potential [1114]. This is extremely important to
keep in mind when considering MSC therapeutic capacity [14],
When contemplating MSC therapeutic modes of action, it is likely
that MSC anti-inflammatory function works in concert with MSC tis-
sue-building capacity. These functions are elaborated in part by chemo-
kines, which are vital in attracting immune cells, such as monocytes
(CCL2) and neutrophils (CXCL2) [13]; immune-modulating factors, such
as prostaglandin E2 [15] and indolamine 2,3-dioxygenase (IDO) [16];
and a variety of angiogenic factors, including vascular endothelial
growth factor and CXCL8 [14]. These properties are amplified by licens-
ing with various stimulatory factors, including interferon gamma,
tumor necrosis factor alpha and IL-1b. Response to these cytokines can
be variable depending on the tissue source [1719]. The authors
recently conducted a comparative analysis of adipose- and umbilical
cord-derived MSCs for differential expression of a suite of chemokines
and immune-modulating and angiogenic factors [14]. Anti-inflamma-
tory and pro-angiogenic phenotypes correlated with positive outcomes
in a transplant model [14]. These methods are yet to be applied to
MSCs derived from other tissues.
Pancreatic-derived MSCs have been described by a number of
groups [19,20]. They can be isolated fromwaste products of pancreatic
islet transplantation. Islet transplantation is used to treat individuals
with type 1 diabetes mellitus with unstable glycemic control [21,22]. It
is an efficacious treatment involving enzymatic dissociation of donor
pancreata under Good Manufacturing Practice (GMP) conditions to
release islets for transplantation [22]. Highly pure islets are trans-
planted into recipients, leaving a fractionated byproduct of digested
exocrine tissue and low-purity islets (LPIs)—small numbers of islets
plus attached exocrine tissue. In this study, the authors investigated
the potential of using the LPI fraction as starting material for GMP-
compliant manufacture of MSC. The authors determined that LPI mate-
rial can be used to manufacture MSCs under GMP conditions at scale.
LPI MSCs expanded using GMP-compatible reagents were systemati-
cally evaluated for their pro-regenerative and inflammation-modulat-
ing function compared with BMMSCs in vitro and in vivo.
Methods
Tissues and blood samples
Research protocols and adherence to donation and ethical consent
specific to the tissues used in this study were regulated by the Scottish
National Blood Transfusion Service (SNBTS) Research Sample Gover-
nance Committee. Non-transplantable LPIs were collected from waste
fractions of the pancreatic islet transplant process, following processing
of donated organs for clinical transplant [21,22]. These tissues were
made available for research following informed written consent, andtheir use was governed under SNBTS sample governance reference num-
bers 12-16 and 15-21. Human volunteer-donor buffy coat was used as a
source of peripheral blood mononuclear cells (PBMCs) for T-cell
responder assays, and chemotaxis assays and were obtained from SNBTS
blood processing under sample governance reference number 14-02.
Human platelet lysate
Platelet lysate supplement was produced by repeatedly freezing
date-expired human platelet packs, (manufactured in-house by
SNBTS) at 80°C for 12 h and thawing at room temperature. The
freeze/thaw cycles were repeated 3 times. Upon final thaw, 10 plate-
let donation packs were pooled and centrifuged at 350 £ g before
decanting the supernatants as 50-mL aliquots and storing at 40°C.
Culture medium
LPI MSCs were derived, maintained and compared in the follow-
ing culture media: (i) DMPL-Dulbecco’s Modified Eagle’s Medium
(Thermo Fisher Scientific) supplemented with heparin (Leo Labs) at a
final concentration of 21 U/mL, non-essential amino acids 1£
(Thermo Fisher Scientific) and 5% human platelet lysate; (ii) SM-
StemMACS MSC expansion media kit XF (Miltenyi Biotec Ltd); and
(iii) SMPL-StemMACS MSC expansion media kit XF supplemented
with 5% human platelet lysate. Unless stated otherwise, studies show
LPIs and BMMSCs maintained in SMPL.
Tissue processing and culture initiation
Pancreatic material
Waste LPI fractions were received from the SNBTS islet isolation lab.
LPIs were washed once in SMPL medium, centrifuged at 300 £ g for
5 min and then cultured at 0.006 mL/cm2 at 37°C in 5% CO2 in SMPL
medium (e.g., 0.45 mL LPI fraction in a T-75 flask plus 9.5 mL SMPL
medium). Explant outgrowth was assessed, and adherent cells were
observed migrating from the explanted materials. The medium was
carefully exchanged at day 7 and thereafter changed every 34 days.
Cultures were observed and photographed using an EVOS cell imaging
system (Thermo Fisher Scientific). Once the cultures had reached
8090% confluence, the cells were recovered with a 10-min incubation
at 37°C with 0.13 mL/cm2 TrypLE Select £1 (Thermo Fisher Scientific).
To remove cell debris, the material was passed through a 100-mm cell
strainer (Falcon). The cells were counted using a hemocytometer and
designated passage 0. These cells were either cryopreserved at 1 £ 106
per 2-mL cryovial in CryoStor CS10 (Sigma-Aldrich) or re-cultured at a
density of 3000 cells/cm2 in CellBIND flasks (Corning).
Intensification of MSC manufacturing density
Five donations of LPIs were processed at a higher reseeding den-
sity of 5000 cells/cm2 in SM +/ platelet lysate medium at only pas-
sage 1 and passage 2.
Bone marrow MSCs
Existing stocks of BM MSC isolates were used in this study for
comparison. These cell populations had been previously generated
up to passage 3 using standard methods [1].
Medium change/passage
All media were changed twice per week. On reaching 8090%
confluence, cultures were collected as described previously, cell
count and yield per flask determined, and reseeded at a density of
3000 cells/cm2 in CellBIND flasks (Corning). Cells were expanded con-
tinually in culture until at least 3 passages of complete cycles of
growth to confluence had been achieved after passage 0. Unless
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out this study.
Trilineage differentiation
MSCs were assessed for differentiation capacity using the human
mesenchymal stem cell functional identification kit (R&D Systems).
This kit contains all necessary differentiation supplements and pri-
mary and secondary antibodies required for detection. The mature
phenotype of adipocytes, chondrocytes and osteocytes were defined
by the binding of antibodies against fatty acid-binding protein 4,
aggrecan and osteocalcin, respectively. Primary antibodies were
detected using secondary antibodies specific to the primary antibody:
NorthernLights 577-conjugated anti-goat (fatty acid-binding protein
4), NorthernLights 557-conjugated donkey anti-mouse (osteocalcin)
and NorthernLights 557-conjugated donkey anti-goat (aggrecan).
Samples were imaged with a Zeiss epifluorescent microscope and
prepared using Zeiss software.
Flow cytometry
Cells were dissociated into a single cell suspension and washed
twice in buffer comprising phosphate-buffered saline (PBS), 2 mM
ethylenediaminetetraacetic acid and 0.1% human serum albumin
(flow buffer). For MSC phenotyping, cells were stained using antibod-
ies at various concentrations (see supplementary Table 1) in a total
volume of 100 uL for 15 min at 4°C. Cells were washed 1 time in flow
buffer and resuspended in 200mL of flow buffer for analysis. Voltages
were set using fluorescence minus 1 control. A minimum of 10000
events were collected. Flow cytometry analysis was performed using
BD LSRFortessa (BD Biosciences) or MACSQuant and analyzed using
FlowJo software (Tree Star).
T-cell suppression assay
T-cell suppression assays were carried out as previously described
[14] using ratios of MSCs to PBMCs ranging from 1:2 to 1:16.
Chemotaxis assay
Whole white blood cells were isolated from fresh buffy coat (see
supplementary Table 1). MSCs were seeded at 3000 cells/cm2 in
DMPL and grown as a monolayer in 24-well plates (Corning). Once
80% confluence was reached, MSCs were either left unlicensed or
licensed. Licensing of MSCs was carried out by incubation of 80% con-
fluent cultures in complete medium supplemented with 10 ng/mL
each of interferon gamma, IL-1b and tumor necrosis factor alpha
(R&D systems). After 24 h, all wells were washed twice with PBS to
remove cytokine, and then 600 mL of fresh DMPL was added to all
wells and left for a further 24 h. Next, 5-mm pore inserts (Thermo
Fisher Scientific) were placed into the wells on top of the MSCs, and
5.5 £ 105 white blood cells in 100 mL DMPL were placed into the
inserts. The transwell plate was incubated at 37°C for 3 h before the
inserts were carefully removed and discarded. Migrated cells were
harvested by collecting the supernatant and washing wells thor-
oughly with PBS, ensuring a collection of loosely adherent cells. Cells
were washed and prepared for flow cytometry using antibodies (see
supplementary Table 1). CountBright beads (50 mL), used per the
manufacturer’s instructions (Life Technologies), were added for cell
counting.
Murine air pouch model
A previously established air pouch model was used to assess in
vivo leukocyte migration induced by transplantation of human MSCs
(see supplementary Table 2) [23]. Next, 1 £ 106 unlicensed orlicensed LPIs or BM MSCs in 1 mL of sterile PBS or sterile PBS alone
(control animals) was injected into the air pouch 24 h after the last
injection of air. Mice were killed and cells collected as previously
described (see supplementary Table 2) after 24 h. Each sample was
split into two and stained for 2 separate flow cytometry panels, one
to identify mouse innate immune cells and one to identify mouse
adaptive immune cells (see supplementary Table 1).
Gene expression
LPIs and BM MSCs were plated at a density of 1 £ 105 cells/cm2 in
DMPL. Once MSCs reached 80% confluence, they were licensed as previ-
ously described or left as unlicensed controls. Cells were incubated for a
further 24 h and then harvested as previously described. Supernatants
were frozen at 80°C for Luminex analysis of protein expression (see
following). Expression of chemokine, cytokine, chemokine receptor and
cytokine receptor genes was assessed using quantitative polymerase
chain reaction and human chemokine and receptor RT2 Profiler poly-
merase chain reaction array (Qiagen) as previously described [12].
Protein secretion
The 24-h conditioned media from identical samples used for tran-
script analysis were collected and analyzed using a Luminex 100 ana-
lyzer (Bio-Rad Laboratories, Inc) and pre-mixed magnetic multi-analyte
kits (R&D Systems) in accordance with the manufacturers’ instructions.
All reagents and standards were included in the kit and prepared as
outlined in the guidelines. Briefly, samples were diluted 2-fold with cal-
ibrator diluent (75 mL in 75 mL). Next, 10 mL of the pre-coated micro-
particle cocktail was added to each well of the 96-well microplates,
followed by either 50 mL sample or 50 mL standard, sealed and placed
on an orbital shaker (0.12-mm orbit at 800 § 50 rpm) for 2 h at room
temperature. The plates were washed twice with 100 mL wash buffer
per well and then incubated with 50 mL anti-biotin detector antibody
per well for 1 h at room temperature on the shaker (0.12-mm orbit at
800 § 50 rpm). The plates were washed as previously described, and
50 mL streptavidin-phycoerythrin was added to each well and incu-
bated for 30 min at room temperature. Microparticles were resus-
pended in 100 mL wash buffer per well and immediately read on the
Luminex 100 analyzer (Bio-Rad Laboratories, Inc). Each microparticle
bead region was designated and doublets excluded as stated on the
certificate of analysis.
Statistics
Graphs and statistical analysis were generated using Prism 6 (Graph-
Pad). Unpaired t-tests were used to compare LPI versus BM material
and paired t-tests utilized when assessing statistical differences within
one tissue source. Significant differences are marked on individual fig-
ures and represented as P < 0.05, P < 0.01 and P < 0.001.
Results
Establishment of human LPI cultures in GMP-compliant medium
In culture, LPI material initially presented as plastic-adherent
islets, identified through positive Dithizone staining and islands of
dithizone-negative exocrine tissue (Figure 1A). Adherent, cobble-
stone-shaped cells grew out from the islets and exocrine tissue as a
monolayer, with longer spindle-shaped cells at the outer edges of the
monolayer (Figure 1A). Flow cytometric analysis of freshly isolated
tissue (day 0) showed that the majority of cells were epithelial cell
adhesion molecule (EPCAM) +ve epithelial cells, and no CD90 or
CD105 +ve cells were detected (Figure 1B). As cultures matured,
EPCAM and MSC marker expression was mutually exclusive, and the
prevalence of CD105, CD90 and CD73 cells went from <1% to >90%,
Figure 1. GMP MSC culture derivation from waste LPI fractions of the islet isolation process. (A) Phase contrast micrographs of cellular outgrowth from islands of tissue isolated
from LPI fractions. Fourteen days in, culture results in characteristic cobblestone-shaped cells emerging from Dithizone-stained islets and exocrine tissue, forming spindle-shaped
MSC-like cells at edges. Scale bar represents 0.2 mm. (B) Three-parameter flow cytometry analysis of MSC and epithelial markers in LPI fraction over time. Flow cytometry plots
show an increase in cells expressing CD90, CD105 and CD73 and a decrease in EPCAM-expressing cells over time. An overlay of EPCAM (left column) and CD90 (right columns)
shows that MSC and epithelial markers are mutually exclusive. At passage 1, LPI isolates lack EPCAM expression and express CD90, CD105, CD73 and vimentin.
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to <0.3%, over a period of 16 days (Figure 1B). At passage 0, the
majority of cells were positive for MSC markers, where 95% of cells
were vimentin +ve and <1% were EPCAM +ve (Figure 1B).
LPI-derived cells could be reliably established in GMP-compliant
media (DMPL, SM and SMPL), where doubling rate was consistent
across all 3 passages (Figure 2A). LPI MSCs grown in SMPL, however,
returned significantly higher colony-forming unit fibroblasts at pas-
sage 2 and passage 3 compared with DMPL and SM (Figure 2B).
There were no differences in colony-forming unit fibroblasts
between LPI MSCs and BM MSCs grown in SMPL at any of the 3 pas-
sages assessed (Figure 2C). LPI cells established in SMPL displayed a
characteristic MSC-like phenotype, through plastic adherence and
spindle-shaped morphology, akin to that of BM MSCs grown in
SMPL (Figure 3A).
LPI cultures also expressed all the relevant MSC markers, includ-
ing positive expression of CD73, CD90 and CD105 and no expression
of CD45, CD19, CD11b, CD34, CD14 or CD31. This MSC surface
marker expression was maintained, and EPCAM expression was
consistently lacking through all passages (Figure 3B). LPI-derived
cell expression levels of all the aforementioned markers were simi-
lar to BM MSCs at passage 3 (Figure 3B). Finally, to confirm that LPI-
derived cells were MSCs, LPI cultures were differentiated into the 3
classical lineages: bone, cartilage and adipose. Positive expression
of fatty acid-binding protein 4, osteocalcin and aggrecan (Figure 3C)
confirmed successful differentiation into all 3 lineages; thus, LPI cul-
tures were considered MSC-like cells and are referred to as LPI MSCs
throughout the article.LPI MSCs and BM MSCs express a range of immunomodulatory and pro-
regenerative factors
To understand whether LPI MSCs display therapeutically desirable
regenerative and immunomodulatory potential, they were assayed for
their transcriptional and protein expression of immune-modulating and
pro-regenerative factors, with and without licensing, and compared
with BM MSCs at the same passage (Figure 4A,B). Unlicensed LPIs and
BMMSCs expressed similar transcriptional patterns of chemoattractant/
inflammation-modulating molecules, with the exception of CX3CL1
(fractalkine) and IL-16, which were transcribed at marginally higher lev-
els in the LPI MSCs. Upon licensing, both MSC types uniformly upregu-
lated the inflammatory regulators tumor necrosis factor-inducible gene
6 (TSG-6) and IDO. Patterns in the transcript expression of the pro-
angiogenic CXC chemokines were almost identical between LPIs and
BMMSCs, where CXCL8was themost highly transcribed pro-angiogenic
gene in LPIs and BMMSCs with or without licensing (Figure 4A).
Various monocyte (CCL2), macrophage (CCL4), dendritic cell
(CCL20) and neutrophil chemoattractants (CXCLs 1, 2, 3, 5, 6 and 8)
were upregulated upon LPI and BM MSC licensing (Figure 4A). Condi-
tioned media from the same cells used in transcriptional analyses
were tested for a selection of pro-angiogenic and chemotactic factors.
Secreted proteins from licensed LPIs and BM MSCs closely tracked
the transcriptional observations, with high amounts of CCL2, CCL20
and CXCL8 detected in unlicensed MSC supernatants, which were
markedly upregulated upon licensing. Vascular endothelial growth
factor, a pro-angiogenic factor, was also produced in moderate
amounts by resting and licensed MSCs from either source (Figure 4B).
Figure 2. LPI MSC growth characteristics in GMP-compliant media and comparison with BMMSCs. (A) Mean population doubling time for LPI MSC lines in 3 different GMP-compli-
ant media (n = 7). (B) Colony-forming unit scores for LPI MSCs grown in DMPL, SM and SMPL across 3 passages (P1P3) with numbers of colonies obtained from plating 10 cells/
cm2 in CFU-F (n = 5). (C) Colony-forming unit scores for LPI MSCs versus BM MSCs, both grown in SMPL, across 3 passages (n=9). Data presented as mean § SD, and significance
marked where applicable. *P < 0.05, **P < 0.01, ***P < 0.001. CFU-F, colony-forming unit fibroblast; DMEM, Dulbecco’s Modified Eagle’s Medium; DMPL, DMEM with 5% platelet
lysate; SM, StemMACS; SMPL, StemMACS with 5% platelet lysate; P, passage; SD, standard deviation.
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both in vitro and in vivo
Chemotaxis assays were utilized to assess whether LPIs and BM
MSCs were able to induce migration of immune cells. Unlicensed LPIFigure 3. Morphology, surface marker expression and differentiation capability of LPI MSCs
(left) similar to that of BMMSCs at P2 (right) . Scale bar represents 400mm. (B) Representativ
panels). LPI MSCs homogeneously express CD90, CD105 and CD73, showing MFI similar to
CD19 and CD14. Lack of EPCAM expression by LPI MSCs is maintained through passage. (C) Fl
chondrocyte lineages (FAB-4, osteocalcin and aggrecan, respectively). Matched isotype contr
FAB-4, fatty acid-binding protein 4; MFI, mean fluorescence intensity; P, passage SMPL, StemMSCs differed markedly from BM MSCs in attracting significantly
more CD45 +ve cells, specifically neutrophils and monocytes. Upon
licensing, both LPIs and BM MSCs attracted neutrophils and mono-
cytes, with little to no attraction of B cells, T cells, natural killer (NK)
cells or eosinophils (Figure 5A). LPI MSCs attracted proportionately. (A) LPI isolate at P1 showing plastic-adherent cells with spindle-like MSC morphology
e phenotypes of LPI MSCs at P3P5 (top panels) compared with BMMSCs at P3 (bottom
that of BM MSCs, and >99% of LPI MSCs lack expression of CD45, CD11b, CD31, CD34,
uorescence micrographs of trilineage differentiation of LPI MSCs into adipose, bone and
ols shown in bottom left inserts. Scale bar detailed in each picture. Cells grown in SMPL.
MACS with 5% platelet lysate.
Figure 4. Gene and protein expression of chemoattractant, pro-inflammatory and anti-inflammatory genes in LPIs and BMMSCs. (A) Gene expression by resting and licensed MSCs.
The expression of chemoattractant and pro-angiogenic genes by resting () and licensed (+) LPIs and BM MSCs (P3) was measured using the RT2 Profiler PCR array. The expression
of anti-inflammatory genes was measured using qRT-PCR as indicated. In each case, the mean 2(-DCT) was plotted and heatmaps generated using Heatmapper software. Each group
of genes was analyzed separately (n >3<6 donors). (B) Mean levels of chemoattractant and pro-angiogenic proteins detected by Luminex assay in 24-h supernatants harvested
from the cultures detailed previously. Data represent total concentration of protein minus background levels of each protein found in medium. Analyzed by Heatmapper software
as previously noted (n >3<6 donors). P, passage; qRT-PCR, quantitative real-time polymerase chain reaction; TSG-6, tumour necrosis factor-inducible gene 6; IDO, indoleamine 2,3-
dioxygenase; CFH, complement factor H; CD274, cluster of differentiation 274; HGF, hepatocyte growth factor; TGF-b, transforming growth factor beta; C5, complement component
5; IL4, interleukin 4; IL1b, interleukin-1 beta; IL16, interleukin 16; VEGF, vascular endothelial growth factor.
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significance.
To establish if observed in vitro behaviors of LPIs and BM MSCs
persisted in vivo, this analysis was extended to a murine air pouch
model. In contrast to in vitro data, unlicensed LPIs and BM MSCs
attracted similar total numbers of all immune cells, with no signifi-
cant differences detected. As observed in vitro, licensing LPIs and BM
MSCs resulted in a marked upregulation in the ability of MSCs to
induce migration of all immune cells. No significant differences in the
total number of immune cells migrating toward licensed LPIs or BM
MSCs were observed, with the exception of licensed BM MSCs
attracting significantly more NK cells than licensed LPI MSCs. Notably,
similar to in vitro migration data, neutrophils and monocytes made
up the majority of immune cells migrating toward licensed or unli-
censed LPIs and BM MSCs; however, the migration of moderate num-
bers of B cells, NK cells and eosinophils was also observed in vivo
(Figure 5B).
LPI MSCs are potent suppressors of T-cell proliferation
Suppression of T-cell proliferation by LPIs after activation with the
T cell mitogen PHA (Phytohaemagglutinin P) was assessed and com-
pared with BM MSCs. The authors first investigated the capacity of
MSCs to suppress T-cell proliferation without licensing. Figure 6Ashows representative flow cytometry plots of T cell proliferation
under the different conditions. Both LPIs and BM MSCs strongly sup-
pressed T-cell proliferation, at MSC to PBMC ratios of 1:2, and the
effect titrated with reducing numbers of MSCs (Figure 6B). Suppres-
sion of proliferation by LPI MSCs was significantly higher, at 1:8, than
that seen with BM MSCs. Given that strong suppressive effects were
seen with unlicensed MSCs, the authors further investigated the role
that licensing plays in MSC suppression of T-cell proliferation. Over-
all, licensing MSCs had no beneficial or detrimental effect on T-cell
suppression mediated by MSCs compared with unlicensed MSCs, and
no significant differences were observed between LPIs and BM MSCs
at any ratio tested (Figure 6C).
GMP-compliant method and density intensification scale up for
manufacturing
To scale up for manufacturing, a suitable volume of LPI tissue and
subsequent reseeding densities of LPI MSCs had to be determined. Ini-
tially, LPI tissue was tested at a density of 0.006 mL/cm2 or 0.03 mL/
cm2 (1 mL or 5 mL total LPI fraction per T-175 flask in a total volume
of 35 mL). Cells were more readily established using the lower seeding
density of 0.006 mL/cm2 (data not shown). Therefore, to model a com-
plete manufacturing process, 1 mL of LPI tissue was seeded into a T-
175 flask (0.006 mL/cm2) and thereafter reseeded at 5000 cells/cm2.
Figure 5. In vitro and in vivo immune cell attraction of LPI and BM MSCs. (A) In vitro chemoattraction of peripheral WBCs. Representative composition of WBCs added to transwell
insert at start of chemotaxis experiments. Migration of WBCs to LPI or BMMSCs in the unlicensed () or licensed (+) state. Data are presented as mean§ SEM and represent the total
number of migrated cells minus the total number of background migrated cells. (B) In vivo air pouch model showing the total numbers of migrated immune cells in the air pouch
containing licensed or unlicensed LPI or BM MSCs. Data are presented as the total number of each migrated immune cell minus the total numbers in PBS-injected control mice.
Stacked bars represent mean § SEM; n = 2 for each MSC donor and 5 mice per group. WBCs, white blood cells; SEM, standard error of the mean.
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72 £ 106 and 4.7 £ 106 (Figure 7A). MSCs grown as described previ-
ously reached median yields of 5200 £ 106 by passage 2 (Figure 7A).
As waste tissue from successful islet isolation ranges from 6 mL to
22 mL (Figure 7B), theoretical yields of LPI MSCs at passage 2 could
range from 37000 £ 106 (6 mL) to 116000 £ 106 (22 mL) (Figure 7C).
Cells manufactured in this way maintained the CD45 ve HLA-DR
ve, CD73+, CD90+ CD105+ phenotype (Figure 7D).
Discussion
In this study, the authors have shown that LPI MSC cultures can be
easily initiated, and the cells can be expanded to therapeutic scale at
low passage. The authors have extensively compared phenotype and
function of LPI MSCs with BM MSCs and shown that LPI MSCs share
therapeutically relevant characteristics with BMMSCs.
Derivation of LPI-MSCs
MSC-like cells isolated from pancreatic tissue have been described
by several groups [19,20]. The authors sought to expand on this work
to produce GMP-grade MSC cell populations rather than to repro-
gram these cells into, for example, beta-like cells. In vitro-expanded
pancreatic MSC populations may arise from small numbers of resi-
dent MSCs or as a result of epithelial-mesenchymal transition (EMT);
this has been explored elsewhere [2427]. The phenotypic changesof LPI isolates described in this study point to EMT as the principal
mechanism underlying the derivation of LPI MSC cultures. The
authors have shown that freshly isolated LPI tissue lacks cells
expressing the mesenchymal markers CD105 and CD90 but is rich in
EPCAM +ve cells. Over the 16-day in vitro expansion period to reach
passage 0, EPCAM +ve cells gradually became positive for CD90 and
CD105, followed by a reduction in EPCAM-staining cells to <1% of the
total population, which was maintained throughout subsequent pas-
sages. At passage 0, over 91% of cells expressed the definitive mesen-
chymal marker vimentin. From passage 1 onward, MSCs expressed
CD105, CD90 and CD73. It is therefore most likely that the LPI MSC
manufacturing processes described in this study produced isolates of
culture-induced MSC-like cells as a result of in vitro EMT, although
involvement of small populations of precursors cannot be entirely
ruled out.
Function and phenotype
International Society for Cell & Gene Therapy criteria for definition
of MSCs [28] have underpinned all recent MSC research, and the LPI
MSCs generated in this study met all of these criteria. Phenotype
alone does not reveal whether MSCs from different sources or MSCs
cultured using different methods have equal therapeutic capacity.
The authors recently reported that umbilical cord-derived MSCs,
when co-transplanted with islets into diabetic mice, have a greater
benefit on glycemic control than identically cultured adipose-derived
Figure 6. Inhibition of T-cell proliferation and requirement for IFN-g licensing. (A) Representative dye dilution results measuring inhibition of T-cell proliferation by LPI or BM
MSCs. Cells were grown in SMPL, assayed at P3 and cultured with Ef670-stained PBMCs. Ratios are PBMC:MSC at outset of culture. (B) Comparative inhibition of T-cell proliferation
by unlicensed LPI or BM MSCs. Both MSC types inhibit proliferation, and the effects titrate with reducing MSC numbers. Mean of 3 different LPI and 4 different BM lines grown in
SMPL. Ratios are PBMC:MSC. (C) Comparative inhibition of T-cell proliferation by licensed LPI or BM MSCs. Mean of 3 different LPI and 4 different BM lines grown in SMPL. Ratios
are PBMC:MSC. IFN-g, interferon gamma; P, passage; PHA, Phytohaemagglutinin P; PBMC,peripheral blood mononuclear cells: SMPL, StemMACS with 5% platelet lysate.
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genes important in immune response and angiogenesis [14]. Here
the authors took a similar standardized approach in the analysis to
systematically compare LPI MSCs with BM MSCs to ensure that they
share clinically applicable characteristics beyond basic phenotyping.
Transcriptional analysis of more than 30 genes highlighted that LPI
MSCs express immunomodulatory, pro-angiogenic and chemotactic
factors similar to BM MSCs. BM and LPI MSCs responded to licensing
with upregulation of a number of genes, including the immune mod-
ulators TSG-6 [29] and IDO [30], the pro-angiogenic and neutrophil
chemoattractants CXCL2 and CXCL8 [31,32] and the monocyte che-
moattractant (and pro-angiogenic) CCL2 [33].
The authors have shown that these transcribed genes translate
into in vitro and in vivo activity of MSCs, with similar patterns in pro-
tein secretion between LPI and BM MSCs. In vitro, strong chemoat-
traction of myeloid cells was a function of licensed LPI and BM MSCs.
In vivo, unlicensed BM and LPI MSCs both induced infiltration of neu-
trophils and monocytes into the injection site. This function was
greatly amplified when MSCs were licensed before injection. Recruit-
ment of inflammatory cells may be an unexpected function of cells
with proven anti-inflammatory properties; however, recruitment of
circulating monocytes has been shown to be critical for microvascular
growth [34]. Moreover, neutrophil recruitment has been shown to be
necessary for blood vessel formation in an in vivo angiogenesis model
[35]. The chemoattraction of immune cells toward MSCs likely serves
more than one purpose, extending beyond angiogenesis to immuno-
modulation of these attracted immune cells, presumably altering the
inflammatory environment. Here the authors have shown that BM
and LPI MSCs not only attract similar types and numbers of immune
cells but also express similar patterns of the immunomodulatory
genes TSG-6, IDO and TGF-b while exerting similar capacity tosuppress T-cell proliferation. The ability of MSCs to attract immune
cells and subsequently immunosuppress them is an important thera-
peutic mode of action that has been demonstrated in a model of
GVHD [36]. Treatment of GVHD is an area where LPI MSCs may offer
an advantage over BM MSCs, as LPI MSCs suppressed T-cell prolifera-
tion at lower ratios of T cells to MSCs and attracted more myeloid
cells in an unlicensed state. LPI MSCs could also potentially be used in
islet transplant recipients, as MSCs have been shown to enhance
engraftment and function in experimental models [14]. Patients rou-
tinely receive 2 islet grafts [21]; hence, MSCs could be generated
from the LPIs of the first transplant and used subsequently as MHC-
matched accessory cells to support the second graft, with potentially
reduced immune sensitization compared with third-party MSCs.
Manufacture of LPI MSCs
Extending the applications of a donated pancreas beyond high-
purity islet transplantation to involve the manufacture of MSCs
from the LPI fraction would extend clinical application of the
donated organ to potentially treat many patients. Recent registry
data indicate >2600 donated pancreata for islet processing (North
America, Europe and Australia) [37] over a 10-year period ending
2015. LPI fractions are therefore routinely available from transplant
centers and should be readily available for distribution to
manufacturing centers. LPI-MSCs grow rapidly in xenogeneic-free
medium; a single T-175 flask initially seeded with 1 mL of LPIs can
generate 5.2 £ 109 cells after 2 in vitro passages, with theoretical
yields from a single LPI fraction of 31.7 £ 109 to 116 £ 109. This
would result in sufficient MSCs to manufacture 3561303 doses
(based on 1 £ 106 cells/kg and a patient weighing 89 kg). This com-
pares favorably with projected manufacturing yields for BM MSCs
Figure 7. Intensification of manufacturing with GMP reagents. (A) Total cell yields from 1 mL of LPI tissue from P0 to P1 in GMP-compliant medium. (B) Total milliliters of trans-
planted tissue versus waste tissue in the GMP islet isolation process. (C) Predicted cell yields from the lowest volume of waste tissue (6 mL) over 2 passages and the highest volume
of waste tissue (22 mL) over 2 passages. (D) Flow cytometric analysis of LPI MSCs grown using the intensified method, demonstrating negativity for hematopoietic markers and
homogeneous expression of CD73, CD90 and CD105. SMPL medium passage 3. GMP, good manufacturing practice; P, passage; SMPL, StemMACS with 5% platelet lysate.
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mL) and standard culture vessels: 6.6 £ 109 at passage 2 and up to
6.3 £ 109 at passage 1 [3,6]. Manufacture of MSCs, irrespective of
source, at this scale would become impractical using standard cul-
ture vessels and would benefit from the use of bioreactors, not nec-
essarily to increase yield—although this is not guaranteed [34]—but
for ease of handling and speed of processing. Manufacturing on a
very large scale may well not be required in a single center, as a sin-
gle LPI fraction from a donated pancreas could support manufactur-
ing in a number of different centers. Samples from a single isolation,
in simple storage media, are routinely distributed fresh from the
SNBTS islet isolation lab around the UK to multiple centers, subject
to appropriate consent.
In summary, the authors have demonstrated that MSCs derived
from LPI fractions exhibit many of the ideal immune-responsive and
pro-regenerative functions of MSCs in vitro and in vivo. These cells
are readily expanded from donated clinical-grade material that is
currently an unused byproduct of islet isolation, and the authors
have demonstrated their successful manufacture using fully GMP-
compliant materials to therapeutic dose at low passage. Further stud-
ies will be required to determine the therapeutic potency of this
novel MSC population.Funding
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